MedicineNews.net - Medical Updates

Lurbinectedin has shown noteworthy clinical activity in metastatic breast cancer with mutations in BRCA 1/2

Lurbinectedin ( Zepsyre ) has shown noteworthy clinical activity in patients with metastatic breast cancer that have mutations in the BRCA 1 and/or BRCA 2 genes. A phase II trial has assessed the c ... read article

Tivozanib in combination with Nivolumab in renal cell carcinoma: interim results from phase 2 portion of the TiNivo trial

Updated interim results from the phase 2 portion of the TiNivo study, a phase 1b/2 multicenter trial of oral Tivozanib ( Fotivda ) in combination with intravenous Nivolumab ( Opdivo ), an immune check ... read article

Cosentyx label update in European Union to include dosing flexibility in psoriatic arthritis

The European Commission has approved a label update for Cosentyx ( Secukinumab ). Cosentyx is the first and only fully-human treatment that specifically inhibits interleukin-17A ( IL-17A ), in psoriat ... read article

Larotrectinib, a TRK inhibitor, in children and adults patients with NTRK fusion cancer

Larotrectinib is being investigated to potentially treat adult and pediatric patients with locally advanced or metastatic solid tumors with a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion ... read article

Tanezumab for the treatment of osteoarthritis pain

A 16-week phase 3 study in patients with osteoarthritis pain evaluating subcutaneous administration of Tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. ... read article

First two CAR-T cell medicines approved in the European Union: Kymriah and Yescarta

The European Commission ( EC ) has approved the first two marketing authorisations for chimeric antigen receptors ( CAR ) T-cells medicines in the European Union ( EU ). Kymriah ( Tisagenlecleucel ... read article

SOLAR-1 trial: alpha-specific PI3K inhibitor Alpelisib has met primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

The global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor Alpelisib ( BYL719 ) has met the primary endpoint showing an improvement in progression-free survival ( ... read article

TRANSITION trial: Entresto can be safely initiated shortly after an acute heart failure episode

Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich, Germany, have shown that Entresto ( Sacubitril / Valsartan ) can be initiated early and safel ... read article

FDA has approved Rituxan for pemphigus vulgaris

The FDA ( U.S. Food and Drug Administration ) has approved Rituxan ( Rituximab ) for the treatment of adults with moderate to severe pemphigus vulgaris, a rare, serious, potentially life-threatening c ... read article

ARCTIC trial in third-line non-small cell lung cancer: Durvalumab monotherapy showed a clinically-meaningful reduction in the risk of death compared to chemotherapy

Results from the phase III ARCTIC trial in patients with locally-advanced or metastatic non-small cell lung cancer ( NSCLC ) who have received at least two prior treatments, were announced. This rand ... read article

Pembrolizumab improves overall survival and progression-free survival as first-line treatment for squamous non-small cell lung cancer (NSCLC) in KEYNOTE-407 trial

The pivotal phase 3 KEYNOTE-407 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with Carboplatin-paclitaxel or nab-Paclitaxel, as first-line treatment for metastat ... read article

Tivozanib, a VEGF tyrosine kinase inhibitor, for the treatment of adult patients with advanced renal cell carcinoma

Tivozanib ( Fotivda ) is an oral, once-daily, vascular endothelial growth factor ( VEGF ) tyrosine kinase inhibitor ( TKI ) for the treatment of adult patients with advanced renal cell carcinoma ( RCC ... read article

Symdeko to treat the underlying cause of cystic fibrosis in people ages 12 and older with certain mutations in the CFTR gene: FDA approved

The U.S. Food and Drug Administration ( FDA ) has approved Symdeko ( Tezacaftor / Ivacaftor and Ivacaftor ) for treating the underlying cause of cystic fibrosis in people ages 12 and older who have tw ... read article

Tymlos for the treatment of postmenopausal women with osteoporosis at high risk for fracture

The FDA ( US Food and Drug Administration ) has approved Tymlos ( Abaloparatide ) injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of ... read article

HER2-positive breast cancer: Neratinib, little benefit and severe toxicity

The FDA ( U.S. Food and Drug Administration ) has approved 1 year of extended adjuvant Neratinib ( Nerlynx ) after chemotherapy and a year of Trastuzumab ( Herceptin ) for HER2-positive breast cancer ... read article